Incyte Corporation: Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients

SYDNEY, Australia--(BUSINESS WIRE)--Results from a 14-day Phase IIa clinical trial, presented today at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, demonstrate that INCB9471, an investigational drug for the treatment of HIV-1, the retrovirus that causes the acquired immunodeficiency syndrome, AIDS, provided a significant decline in viral load when used as monotherapy in 19 HIV-infected subjects, including ten treatment-naïve and nine treatment-experienced patients not currently on antiviral therapies.

MORE ON THIS TOPIC